Biotech

Dynavax Technologies reported their financial results for the second quarter of 2017.

Dynavax Technologies (NASDAQ:DVAX) reported their financial results for the second quarter of 2017.
As quoted in the press release:

Cash, cash equivalents and marketable securities were $127.0 million at June 30, 2017 compared to $81.4 million at December 31, 2016. The increase was primarily due to net proceeds of $88.2 million during the first half of 2017 from sales of common stock under an at-the-market sales agreement.
Additional Financial Results
The net loss for the three months ended June 30, 2017 was $20.3 million, or $0.41 per share, compared to $29.0 million, or $0.75 per share, for the same period in 2016. The net loss for the six months ended June 30, 2017 was $45.6 million, or $1.00 per share, compared to $56.0 million, or $1.46 per share, for the same period in 2016.
Research and development expenses for the quarter and six months ended June 30, 2017 were $14.8 million and $31.2 million, respectively, compared to $22.8 million and $42.8 million for the same periods in 2016. The decrease in the 2017 periods reflect reduced compensation and related personnel costs as a result of the January 2017 restructuring and cost reduction initiative. Additionally, the 2017 periods reflect lower costs related to HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] clinical and manufacturing activity partially offset by increased costs relating to seeking regulatory approval for HEPLISAV-B and the ongoing development of SD-101 and earlier stage oncology programs.

Click here to read the full press release.

Source: www.marketwired.com

Featured

MARKETS

Markets
TSX20145.02+445.97
TSXV701.81+34.56
DOW32156.05+425.75
S&P 5004026.53+96.45
NASD11821.19+450.22
ASX6941.00-123.70

COMMODITIES

Commodities
Gold1810.80-9.68
Silver20.99+0.19
Copper4.17+0.07
Palladium1951.50+18.50
Platinum944.00-3.00
Oil110.26+4.13
Heating Oil3.79+0.06
Natural Gas7.67-0.07

DOWNLOAD FREE REPORTS

×